文献速递前列腺癌

新西兰前列腺癌主动监测项目结局与进展预测因素

Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.
PubMed 文献 · BJU Int · 2026-04-15

该回顾性研究纳入296例ISUP GG1前列腺癌主动监测患者,平均随访7.4年,36.5%发生组织学进展,33.4%需治疗。PSA密度≥0.15 ng/mL/mL和PIRADS 3-5病灶是进展的独立预测因素,低危亚组进展率17.2%。

要点

  • PSA密度≥0.15 ng/mL/mL与PIRADS 3-5病灶是组织学进展的独立预测因素。
  • 低危亚组(低PSA密度且无可疑MRI病灶)仍有17.2%进展至ISUP≥2。
  • 阳性针百分比所反映的肿瘤体积并非独立预测因素。

核心结论

  • 主动监测是低危前列腺癌的安全选择,结局与登记数据及国际数据一致。
  • PSA密度和多参数MRI是进展的最强预测因素,肿瘤体积百分比非独立预测。

研究设计与样本

  • 新西兰North Shore Hospital主动监测项目的回顾性研究(2014-2020),2024年查阅记录。
  • 共纳入296例ISUP GG1前列腺癌主动监测患者。

主要发现

  • 平均随访7.4年,36.5%发生组织学进展至ISUP≥2,33.4%需治疗,12.1%治疗后复发,1例死于转移性疾病。
  • 93例低危亚组(低PSA密度且无可疑MRI病灶)中16例(17.2%)进展。
  • 多因素分析显示PSA密度≥0.15 ng/mL/mL的OR为3.45,PIRADS 3-5病灶的OR为3.52。

关键数值与推荐

  • 进展独立预测因素:PSA密度≥0.15 ng/mL/mL(OR 3.45),PIRADS 3-5病灶(OR 3.52)。
  • 新西兰草案指南建议PSA密度<0.15 ng/mL/cc且MRI无PIRADS 3-5病灶者不行活检。

临床怎么用

  • 主动监测中应结合PSA密度和多参数MRI评估进展风险。
  • 低PSA密度且无可疑MRI病灶者仍不可忽视密切监测,因本队列进展率17.2%。

局限性

  • 回顾性单中心研究,样本量296例,随访7.4年。
  • 低危亚组样本量93例,进展事件数较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe outcomes and identify predictors of histological progression in men on active surveillance (AS) for International Society of Urological Pathology Grade Group (ISUP GG) 1 prostate cancer in New Zealand (NZ), as AS is the standard management for favourable-risk prostate cancer, yet NZ-specific outcome data remain limited. PATIENTS AND METHODS: A retrospective study of the North Shore Hospital AS programme (2014-2020) was conducted. Records were reviewed in 2024. In total, 296 men with ISUP GG 1 disease on AS were included. Primary endpoints were histological progression to ISUP GG ≥2, treatment conversion, and disease-related mortality. RESULTS: Over a mean 7.4-year follow-up, 36.5% progressed, 33.4% required treatment, 12.1% recurred after treatment, and one patient died from metastatic disease. Within the cohort, a low-risk subgroup of 93 patients with ISUP GG 1 prostate cancer had low prostate-specific antigen (PSA) density and no suspicious magnetic resonance imaging (MRI) lesions. Of these patients, 16 (17.2%) progressed. On multivariate analysis, independent predictors of progression were PSA density ≥0.15 ng/mL/mL (odds ratio [OR] 3.45) and Prostate Imaging-Reporting and Data System 3-5 lesions (OR 3.52). CONCLUSION: Active surveillance is a safe option for low-risk prostate cancer, our data are consistent with outcomes consistent with the Prostate Cancer Outcomes Registry and international data. PSA density and multiparametric MRI were the strongest predictors of progression; tumour volume by percentage of positive cores was not independently predictive. New draft Prostate Cancer Foundation of Australia guidelines recommend against biopsy in men with PSA density <0.15 ng/mL/cc and no PIRADS 3-5 lesion on MRI[7], in our cohort this included many men with ISUP 1 cancer. They had a 17.2% progression rate to ISUP ≥2, and their clinically significant disease might have been missed without close surveillance.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Xu K, Shah N, Han DY, et al. Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer. BJU Int. 2026. PMID: 41983272. doi:10.1111/bju.70276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。